Risk factors, pathogenesis, and botanical drugs interventions for postoperative pulmonary complications after cardiothoracic surgery: a narrative review Authors: Haoran Wang, Zhongyi Liang Published: 2026 ABSTRACT Background and ObjectivePostoperative pulmonary complications (PPCs) are common and severe after cardiothoracic surgery, leading to prolonged hospital stays, increased medical burden, and elevated mortality. Driven by patient-related, surgery-related, and perioperative factors, PPCs are characterized by a pathophysiology involving inflammation, oxidative stress, alveolar injury, and airway obstruction. This review aims to systematically summarize PPCs’ risk factors, pathogenesis, and the role of botanical drugs, providing a scientific basis for clinical decision-making.MethodsRelevant literature published from 2010 to 2025 were searched in PubMed, Embase, Web of Science, and Cochrane Library using keywords such as “Postoperative pulmonary complications (PPCs)”, “Botanical drugs”, “Pathogenesis”, “Risk factors”, and “Cardiothoracic surgery”. Eligible English studies [randomized controlled trials (RCTs), cohort studies, systematic reviews, etc.] were included, with low-quality studies and those unrelated to cardiothoracic surgery excluded. Quality assessment was performed using A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR-2), Newcastle-Ottawa Scale (NOS), and Risk of Bias Tool 2.0 (RoB 2), and 55 studies were finally included for data extraction and synthesis.Key Content and FindingsKey PPCs risk factors include patient-related [age ≥65 years, chronic obstructive pulmonary disease (COPD), smoking history], surgery-related [extensive resection, prolonged one-lung ventilation (OLV)], and perioperative factors (inadequate analgesia, prolonged bed rest). Core pathophysiological mechanisms involve Toll-like receptors (TLRs) and the nuclear factor-κB (NF-κB) pathway-mediated inflammation, excessive reactive oxygen species (ROS)-induced oxidative stress, alveolar type II cell dysfunction, and airway obstruction. Botanical drugs (e.g., Huanglian Jiedu Decoction, andrographolide, and Salvia miltiorrhiza extract) exert protective effects against PPCs by modulating inflammatory pathways, scavenging free radicals, and preserving the pulmonary barrier; however, relevant studies are limited by small sample sizes and single-center study designs.ConclusionsPPCs’ pathogenesis is complex, and clarifying their risk factors and mechanisms provides clinical intervention targets. Botanical drugs, with multi-target effects, serve as valuable supplements to modern medicine for PPCs management. Future research should focus on large-sample, multicenter RCTs to validate botanical drugs’ efficacy and safety, and explore integrated Chinese-Western medicine strategies to optimize postoperative recovery. Introduction Postoperative pulmonary complications (PPCs) are defined as clinically significant pulmonary pathological abnormalities that occur following cardiothoracic surgery and adversely affect postoperative recovery (1). The scope of PPCs is broad, primarily encompassing pneumonia, respiratory failure, atelectasis, pneumothorax, pleural effusion, and other conditions. Some studies also include critical types such as acute respiratory distress syndrome (ARDS). Significant variations exist in the definition of PPCs across different studies, which is one of the key reasons for discrepancies in their incidence rates. Pneumonia, the most common infectious complication, occurs in up to 32.21% of cardiothoracic surgery patients admitted to the intensive care unit (ICU), with Clinical manifestations include postoperative fever, purulent sputum production, and elevated white blood cell counts (2). Respiratory insufficiency primarily presents with impaired oxygenation, tachypnea, and cyanosis. In severe cases, it may progress to acute respiratory failure (3). Atelectasis often results from postoperative pain, diaphragmatic dysfunction, or retained secretions, presenting clinically with impaired oxygenation, localized diminished breath sounds, and collapsed lung tissue (4). Pneumothorax and pleural effusion are also common complications, causing sudden chest pain, dyspnea, and decreased oxygen saturation due to pleural injury or fluid accumulation, respectively (5,6). Additionally, ARDS is rare but severe, typically occurring 24–72 hours postoperatively and characterized by refractory hypoxemia and bilateral pulmonary infiltrates (7). Notably, PPCs exhibit marked surgical heterogeneity, with an overall incidence of 15–50% following cardiothoracic surgery; this incidence is higher after lung resection (30–50%), whereas esophageal surgery and thoracoscopic procedures are associated with lower rates (15–25%) (8,9). The occurrence of PPCs is a major contributor to increased postoperative mortality, elevated healthcare costs, and prolonged hospital stays. The high incidence of PPCs underscores the urgency of perioperative risk management. Current main interventions for PPCs include lung-protective ventilation strategies such as low-tidal-volume ventilation, as well as measures like incentive spirometry used in high-risk populations including patients with chronic obstructive pulmonary disease (COPD) (10,11). However, since individual patient factors such as comorbidities, age, and gender are difficult to modify effectively during the perioperative period, relevant research is gradually shifting toward personalized prevention and treatment strategies. Botanical drugs show great potential for the prevention and treatment of PPCs through multiple mechanisms, including anti-inflammatory, immunomodulatory, and antioxidant effects, as well as the promotion of tissue repair, thus providing novel research directions in this field. Therefore, this study aims to systematically review the risk factors and pathogenesis of PPCs, integrating the latest advances in modern medicine and botanical drugs to provide a theoretical foundation and scientific support for their prevention and treatment. We present this article in accordance with the Narrative Review reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0285/rc). Methods Literature search This research searched four databases: PubMed, Embase, Web of Science, and Cochrane Library. The retrieval time span was from 2010 to 2025, with the last search date being December 31, 2025. The literature search was conducted using “Postoperative pulmonary complications (PPCs)”, “Botanical drugs”, “Pathogenesis”, “Risk factors”, and “Cardiothoracic surgery” as keywords and subject headings (Table 1). Table 1The search strategy summaryItemsSpecificationDate of search6 December 2025Databases and other sources searchedPubMed, Embase, Web of Science, and Cochrane LibrarySearch terms usedFree text terms: “Postoperative pulmonary complications (PPCs)”, “Botanical drugs”, “Pathogenesis”, “Risk factors”, and “Cardiothoracic surgery” TimeframeJanuary 2010 to December 2025Inclusion and exclusion criteriaInclusion criteria (I) English literatures published between January 2010 and December 2025 (II) Studies on PPCs after cardiothoracic surgery, including those related to risk factors, pathogenesis, and botanical drug interventions (III) Study types: RCTs, cohort studies, case-control studies, systematic reviews, and meta-analysesExclusion criteria (I) Non-English literatures, duplicates, and conference abstracts without full text (II) Studies on PPCs after non-cardiothoracic surgery (III) Low-quality studies (incomplete data, ambiguous research design, or non-peer-reviewed)Selection processThe selection process involved importing retrieved records into EndNote X9 for automatic deduplication, followed by manual cross-checking by two independent reviewers, who then screened titles/abstracts and full texts to identify eligible studies, with discrepancies resolved through discussion or consultation with a third researcherPPCs, postoperative pulmonary complications; RCTs, randomized controlled trials. The search strategy summary PPCs, postoperative pulmonary complications; RCTs, randomized controlled trials. Inclusion and exclusion criteria for literature Inclusion criteria English literature published from January 2010 to December 2025; English literature published from January 2010 to December 2025; Studies focusing on PPCs after cardiothoracic surgery, including studies related to their risk factors, pathogenesis, and botanical drug interventions; Studies focusing on PPCs after cardiothoracic surgery, including studies related to their risk factors, pathogenesis, and botanical drug interventions; Study types including randomized controlled trials (RCTs), cohort studies, case-control studies, systematic reviews, and meta-analyses. Study types including randomized controlled trials (RCTs), cohort studies, case-control studies, systematic reviews, and meta-analyses. Exclusion criteria Non-English literature, duplicate publications, and conference abstracts without full text; Non-English literature, duplicate publications, and conference abstracts without full text; Studies focusing on PPCs after non-cardiothoracic surgery; Studies focusing on PPCs after non-cardiothoracic surgery; Low-quality studies with incomplete data, ambiguous research design, or non-peer-reviewed literature. Low-quality studies with incomplete data, ambiguous research design, or non-peer-reviewed literature. Quality assessment Two independent reviewers assessed the quality of the included literature using validated tools: The methodological quality of systematic reviews and meta-analyses was evaluated using the AMSTAR-2 scale (graded as high, moderate, low, and critically low); The methodological quality of systematic reviews and meta-analyses was evaluated using the AMSTAR-2 scale (graded as high, moderate, low, and critically low); The Newcastle-Ottawa Scale (NOS) was used to assess the quality of observational studies (cohort studies/case-control studies). The scale has a total score of 9 points, and studies scoring ≥7 points were regarded as high-quality research; The Newcastle-Ottawa Scale (NOS) was used to assess the quality of observational studies (cohort studies/case-control studies). The scale has a total score of 9 points, and studies scoring ≥7 points were regarded as high-quality research; The Cochrane Risk of Bias Tool 2.0 (RoB 2) was used to evaluate the risk of bias in RCTs (graded as low risk of bias, some concerns, and high risk of bias). The Cochrane Risk of Bias Tool 2.0 (RoB 2) was used to evaluate the risk of bias in RCTs (graded as low risk of bias, some concerns, and high risk of bias). Among the 55 included studies, 58.2% were assessed as having a low risk of bias, 30.9% a moderate risk, and only 10.9% a high risk of bias (Table S1). The overall risk of bias was manageable, and the validity of the included literature supported the conclusions of this study. Literature search and data extraction Initially, a total of 332 publications related to the topic of this study were retrieved from four major databases. All retrieved records were imported into EndNote X9 reference management software for automatic deduplication based on title, author, journal name, publication year, and page numbers. Subsequently, two independent reviewers conducted manual cross-checking to exclude potential duplicate records caused by different journal abbreviations and variations in author name spelling, resulting in 320 articles. The two reviewers then screened the titles and abstracts, excluding studies with inconsistent research topics and incomplete data, leaving 125 articles. After full-text reading and comprehensive evaluation of the remaining potentially eligible studies, a total of 55 articles were finally included (Figure 1). Literature flowchart. Finally, two reviewers independently extracted key data from the finally included studies via independent duplicate extraction, including the first author, publication year, study population, core research content, main outcome measures, and other relevant data. Any discrepancies during the above process were resolved through face-to-face discussion to reach a consensus; if no agreement could be achieved, a third researcher was consulted for the final judgment. Risk factors for PPCs following thoracic surgery Patient-related factors Patient-related factors are significant determinants of PPCs in thoracic surgery, encompassing age, underlying medical conditions, smoking history, nutritional status, and immune function (Table 2). Age stands as an independent risk factor for PPCs, with elderly patients (≥65 years) exhibiting a markedly elevated risk of 31–34.9% (12,13). Frail elderly patients are more prone to complications such as atelectasis and pneumonia due to sarcopenia (e.g., impaired diaphragmatic function), dysregulated immune function, and metabolic disorders (24). Furthermore, underlying conditions such as COPD GOLD (Global Initiative for Chronic Obstructive Lung Disease) Stage ≥ III, diabetes, and cardiovascular disease significantly elevate the risk of PPCs (9,14,15). A long history of smoking is another significant risk factor, as it induces chronic airway inflammation that exacerbates postoperative pulmonary adverse reactions (16,17). Malnutrition has been demonstrated as a major risk factor for PPCs, increasing susceptibility to infection and atelectasis by impairing immune function and delaying tissue healing (18,19). Preoperative anemia is also closely associated with PPCs, with hemoglobin levels <97 g/L considered an independent risk factor (20). Immune function critically influences postoperative resistance to infection; impairments such as immunosuppression exacerbate pulmonary inflammation and hypoxia, thereby promoting the development of PPCs (21,22). Several studies have indicated that patients receiving neoadjuvant chemoradiotherapy have a higher incidence of PPCs (23). In summary, age, underlying medical conditions, smoking history, nutritional status, and immune function are all major risk factors for PPCs in thoracic surgery. Strengthening preoperative assessment and management of these factors is crucial for reducing PPCs incidence. Table 2Patient-related risk factors for PPCs following thoracic surgeryRisk factorEffect on PPCsReferencesAge ≥65 yearsIncidence of PPCs ~31–34.9% in elderly patients(12,13)COPD, diabetes, and cardiovascular diseaseFurther increases PPC risk, especially in open thoracotomy(9,14,15)Long-term smokingInduces chronic airway inflammation and aggravates postoperative pulmonary reactions(16,17)MalnutritionIncreases susceptibility to infection and atelectasis; delays wound healing(18,19)Hemoglobin levels <97 g/LIdentified as an independent risk factor for PPCs(20)Immune dysfunctionExacerbates pulmonary inflammation and hypoxia(21,22)Neoadjuvant chemoradiotherapyA higher incidence of PPCs(23)COPD, chronic obstructive pulmonary disease; PPCs, postoperative pulmonary complications. Patient-related risk factors for PPCs following thoracic surgery COPD, chronic obstructive pulmonary disease; PPCs, postoperative pulmonary complications. Surgical-related factors The type and extent of surgery are key factors influencing PPCs (Table 3). Extensive lung resection and complex thoracic procedures, which involve prolonged operative time and significant tissue injury, often result in impaired pulmonary function and heightened inflammatory responses, thereby substantially increasing the risk of PPCs (25,26). Surgical duration represents another critical predictor, with the risk of PPCs rising markedly when surgery lasts more than 3–4 hours (27). Anesthesia modality also substantially influences PPCs. Compared to combined general anesthesia with regional analgesia, general anesthesia alone increases the risk of PPCs (28). Regarding mechanical ventilation, one-lung ventilation (OLV)—a necessary step in thoracic surgery—significantly elevates PPCs risk when prolonged or performed at high driving pressures. Mechanisms include exacerbating pulmonary ischemia-reperfusion injury and promoting alveolar collapse (29). Studies demonstrate that patients undergoing OLV exhibit markedly higher PPCs incidence than those receiving bilateral ventilation, closely correlated with impaired pulmonary function (34,35). In pediatric thoracic surgery, mechanical ventilation exceeding 90 minutes constitutes an independent risk factor for PPCs (36). Furthermore, general anesthesia combined with prolonged mechanical ventilation can cause lung tissue injury and reduced lung compliance (11). Intraoperative blood loss and fluid management also directly influence PPCs occurrence. Massive fluid administration and intraoperative bleeding can lead to pulmonary edema and exacerbate inflammatory responses (30,31). Systematic reviews indicate that restrictive fluid management strategies help reduce PPCs incidence (37). Concurrently, intraoperative temperature control and surgical positioning exert certain effects on postoperative pulmonary function recovery (32,33). In summary, extensive surgical scope, prolonged mechanical ventilation, general anesthesia alone, and excessive fluid administration constitute significant risk factors for PPCs. Optimizing surgical and anesthetic strategies while implementing rational fluid management represent key approaches to reducing PPCs. Table 3Surgery- and anesthesia-related risk factors for postoperative pulmonary complications after thoracic surgeryRisk factorImpact on PPC incidenceReferencesExtensive lung resection and complex proceduresProlonged operative time and greater tissue injury(25,26)Surgery lasts more than 3–4 hoursSignificantly increases the risk of PPCs(27)General anesthesia aloneHigher PPC incidence compared with general anesthesia plus regional techniques(28)Prolonged OLVAggravates ischemia-reperfusion injury and alveolar collapse; increases PPC risk(25-27)Prolonged mechanical ventilationIdentified as an independent risk factor for PPCs in pediatric thoracic surgery(29)Excessive intraoperative fluid administrationLeads to pulmonary edema and aggravates inflammatory responses(30,31)Inadequate temperature control, unfavorable positioningMay impair respiratory muscle function and delay postoperative lung recovery(32,33)OLV, one-lung ventilation; PPCs, postoperative pulmonary complications. Surgery- and anesthesia-related risk factors for postoperative pulmonary complications after thoracic surgery OLV, one-lung ventilation; PPCs, postoperative pulmonary complications. Perioperative management factors Perioperative management strategies also significantly influence the occurrence of PPCs (Table 4). Preoperative forced expiratory volume in one second (FEV1) is a key independent predictor of PPCs. The risk of PPCs is significantly elevated when FEV1%pred <80%, and optimizing pulmonary function in patients with reduced FEV1 can decrease PPCs (38). Studies indicate that thoracic paravertebral block (TPVB) combined with general anesthesia effectively reduces postoperative pain and promotes respiratory recovery, thereby significantly lowering the incidence of PPCs (39). Prolonged bed rest and improper positioning are major contributing factors to PPCs (2). Early mobilization and position management help prevent atelectasis and pulmonary infections. Studies demonstrate that early mobilization improves pulmonary function, shortens mechanical ventilation duration and hospital stay (40,41), and shows positive effects on prognosis in pediatric and geriatric patients (43,44). Rational antibiotic use and infection control are equally critical for reducing PPC risk. Appropriate antibiotic strategies minimize the emergence of resistant bacteria and related infections (42,45). In summary, systematic perioperative management should be advanced synergistically across three dimensions: analgesia strategies, activity and positioning interventions, and rational antibiotic use coupled with infection control. Table 4Perioperative management factors associated with postoperative pulmonary complications after thoracic surgeryRisk factorEffect on PPCsReferencesFEV1%pred <80%The risk of PPCs is significantly elevated(38)TPVB combined with general anesthesiaReduces postoperative pain; facilitates respiratory rehabilitation(39)Prolonged bed restPromotes atelectasis and pulmonary infection(2)Early mobilization and position managementImproves lung function; shortens ventilation duration and hospital stay(40,41)Appropriate prophylactic antibioticsReduces surgical site and pulmonary infections(42)FEV1, forced expiratory volume in one second; PPCs, postoperative pulmonary complications; TPVB, thoracic paravertebral block. Perioperative management factors associated with postoperative pulmonary complications after thoracic surgery FEV1, forced expiratory volume in one second; PPCs, postoperative pulmonary complications; TPVB, thoracic paravertebral block. Pathophysiology of PPCs Inflammatory response and immune dysregulation The inflammatory response is a key pathophysiological mechanism underlying PPCs in thoracic surgery (Figure 2A). Emergency procedures and surgeries lasting over 3 hours are significant risk factors for increased inflammatory activation (46). Surgical trauma directly disrupts the pulmonary tissue barrier, releasing damage-associated molecular patterns (DAMPs). This activates Toll-like receptors (TLRs) and the nuclear factor-κB (NF-κB) pathway, promoting the release of proinflammatory mediators such as interleukin-6 (IL-6), interleukin-12 (IL-12), and tumor necrosis factor-α (TNF-α) (47-49), increasing capillary permeability and leading to pulmonary edema and impaired gas exchange. In the pathogenesis of ventilator-induced lung injury (VILI), mechanical forces such as excessive tidal volume and high driving pressure initiate the biotrauma pathway by activating pulmonary epithelial cells and macrophages to release pro-inflammatory cytokines including IL-6 and TNF-α as well as DAMPs, which amplifies local and systemic inflammation and exacerbates PPCs such as ARDS and pneumonia (50). Key pathophysiological mechanisms of PPCs in thoracic surgery. (A) Inflammation and immunosuppression in PPCs. Surgical trauma disrupts the pulmonary tissue barrier and releases DAMPs, which activate the TLR/NF-κB signaling pathway and trigger a proinflammatory cytokine storm (e.g., IL-6, IL-12, TNF-α). This inflammatory response acts synergistically with tumor-induced immunosuppression, which is more prominent in elderly patients with impaired immune function, increasing capillary permeability and resulting in lung tissue injury and pulmonary edema. (B) Oxidative stress pathways in PPCs. Surgical trauma, IR injury, and high-concentration oxygen inhalation can induce mitochondrial dysfunction, leading to explosive production of ROS such as superoxide anions and hydrogen peroxide. Oxidative stress occurs when ROS production exceeds the scavenging capacity of endogenous antioxidant defense systems, including superoxide dismutase and glutathione. ROS directly disrupts the integrity of pulmonary vascular endothelium, increases capillary permeability, and induces pulmonary edema. Meanwhile, surgical trauma and oxidative stress activate the hypothalamic-pituitary-adrenal axis, promoting cortisol release and hepatic synthesis of CRP, exacerbating systemic inflammation and further aggravating lung injury. (C) Alveolar injury and airway obstruction. Surgical procedures and anesthesia impair the function of type II alveolar epithelial cells, reducing the synthesis and secretion of PS and weakening alveolar structural stability. Concurrently, postoperative mechanical ventilation and inflammatory responses increase airway secretions and mucus viscosity, impairing mucus clearance, causing airway obstruction and alveolar collapse, disrupting ventilation function, and ultimately leading to PPCs. CRP, C-reactive protein; DAMPs, damage-associated molecular patterns; IL-12, interleukin-12; IL-6, interleukin-6; IR, ischemia-reperfusion; NF-κB, nuclear factor-κB; PPCs, postoperative pulmonary complications; PS, pulmonary surfactant; ROS, reactive oxygen species; TLR, Toll-like receptor; TNF-α, tumor necrosis factor-α. Thoracic surgery, as the primary treatment for malignant thoracic tumors, carries an increased risk of PPCs due to the immunosuppressive effects of the malignancy itself and its associated therapies, even when the tumor is successfully resected. This risk is particularly pronounced in elderly patients with compromised immune function, where the impact of malignancy on postoperative PPCs is accentuated (51). In summary, the inflammatory response and immune dysregulation underlying PPCs after thoracic surgery primarily stem from the release of inflammatory mediators triggered by surgical trauma and the disruption of immune cell function. The combined effects of these factors exacerbate pulmonary inflammation and diminish immune defense capabilities, ultimately precipitating PPCs (52). Oxidative stress Surgical trauma, ischemia-reperfusion injury (IR), and high-concentration oxygen inhalation can trigger mitochondrial dysfunction, promoting explosive generation of reactive oxygen species (ROS) clusters such as superoxide anions and hydrogen peroxide (Figure 2B). When ROS production exceeds the scavenging capacity of endogenous antioxidant defenses [e.g., superoxide dismutase (SOD) and glutathione], oxidative stress ensues (53,54). Surgical trauma and oxidative stress activate the hypothalamic-pituitary-adrenal axis, increasing cortisol release and promoting hepatic synthesis of C-reactive protein (CRP), thereby exacerbating systemic inflammatory responses (55). Furthermore, oxidative stress directly compromises pulmonary vascular endothelial integrity, increases capillary permeability, induces pulmonary edema, and impairs vascular barrier function (56). Collectively, postoperative oxidative stress in thoracic surgery, through excessive ROS production, causes pulmonary tissue oxidative damage and apoptosis, compromising gas exchange function and serving as a key mechanism for pulmonary complications. Alveolar damage and airway obstruction Alveolar type II cells synthesize and secrete pulmonary surfactant (PS) (Figure 2C). Surgical procedures and anesthesia impair their function, reducing PS production and thereby weakening alveolar structural stability (57). Concurrently, postoperative mechanical ventilation and inflammatory responses increase airway secretions and mucus viscosity, hindering effective clearance and predisposing to airway obstruction (58). Furthermore, diaphragmatic nerve paralysis following thoracic surgery not only diminishes the efficiency of the cough reflex but also impedes secretion clearance, exacerbating airway obstruction (59). Additionally, surgical trauma suppresses ciliary motility, reducing mucus clearance capacity and leading to secretion accumulation and bronchial obstruction (60). Postoperative incisional pain is another significant factor, as patients often avoid deep breathing and coughing due to discomfort, facilitating secretion accumulation and airway obstruction (11). Collectively, alveolar structural damage and airway secretion obstruction interact to form the key pathological basis for pulmonary complications following thoracic surgery. Key mechanisms of botanical drugs interventions in PPCs Botanical drugs formulas Huanglian Jiedu Decoction exerts dual regulatory effects. On the one hand, it modulates the IL-6/STAT3 pathway to reduce Th17 cell proportions, correct imbalances in immune cell subsets, optimize postoperative immune function, and thereby decrease the incidence of pulmonary infection (61). On the other hand, it regulates the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) signaling pathways to exert its pulmonary protective effects. This mechanism not only regulates the clearance of damaged organelles and maintains intracellular homeostasis but also inhibits caspase-3 activation (62,63). Gegen Qinlian Decoction (GQD) inhibits alveolar epithelial cell apoptosis by activating the PI3K/Akt signaling pathway, upregulating the anti-apoptotic protein Bcl-2, and downregulating the pro-apoptotic protein Bax (64). Chlorogenic acid derivatives in Shuanghuanglian Oral Liquid similarly target the PI3K-Akt signaling pathway. By enhancing the expression and function of tight junction proteins like ZO-1 and occludin, they improve alveolar epithelial barrier integrity, thereby reducing pulmonary edema and inflammatory infiltration to exert protective effects against PPCs (65,66). Fusu Daxiang Decoction focuses on vascular endothelial protection by stabilizing mitochondrial membrane potential (MMP), reducing lactate dehydrogenase (LDH) extravasation, and repairing vascular endothelium, ultimately mitigating vascular endothelial injury associated with acute lung injury (67). Shensu Decoction (SSY) activates the Keap1-Nrf2-ARE signaling pathway, upregulating Nrf2 and its downstream antioxidant-related proteins (NQO1, GCLC, HO-1). This enhances the activity of antioxidant enzymes such as SOD, thereby exerting an anti-lipid peroxidation effect (68). Although compound botanical drugs such as Huanglian Jiedu Decoction and GQD have been proven to exert protective effects against PPCs through multiple signaling pathways, the quality of studies supporting these conclusions is significantly limited. Most of the RCTs cited are single-center studies with relatively small sample sizes, which limits statistical power and makes it difficult to generalize the findings to broader patient populations. In addition, selective reporting bias is common: many studies prioritize positive outcomes (such as reduced levels of inflammatory factors and lower incidence of PPCs) while ignoring non-statistically significant findings or adverse events, further increasing the difficulty of result integration and comparison. Single-botanical drugs Dehydroandrographolide (Deh), a bioactive component of Andrographis paniculata, significantly attenuates mitochondrial damage by modulating the ROS-mtDNA-cGAS/STING signaling pathway. This inhibition of NLRP3-mediated pyroptosis reduces inflammatory responses and tissue injury, thus providing a potential mechanistic basis for PPCs intervention (69). Polyphenol-polysaccharide complexes (PPPCs) extracted from wild strawberry leaves (Fragaria vesca L.) exhibit potent anti-inflammatory activity. Their core mechanism involves inhibiting the release of inflammatory mediators such as IL-6 and CRP, thereby reducing pulmonary inflammation (70). Salvia miltiorrhiza modulates phospholipase Cγ2 (PLCγ2)-phosphatidylinositol 4,5-bisphosphate (PIP2) pathway activity, inhibits NLRP3 inflammasome assembly, reduces caspase-1 activation mediating inflammation, and ultimately decreases proinflammatory cytokine interleukin-1β (IL-1β) secretion, thereby achieving PPCs alleviation (71). Pterostilbene (STR), an extract from the Pterocarpus genus, specifically binds extracellular signal-regulated kinase 2 (ERK2) and inhibits its phosphorylation, thereby regulating the IκB kinase α (IKKα)/inhibitor κB α (IκBα)/NF-κB signaling cascade to exert anti-inflammatory effects (72). Baicalin exhibits potent antioxidant properties. When formulated with disulfiram (DSF) into metal-coordinated nanomedicines and administered via single tracheal intubation, the nanoparticles efficiently accumulate in lung tissue and rapidly penetrate the pulmonary mucosa. This facilitates intracellular free radical scavenging, thereby enhancing cellular resistance to oxidative stress (73). Ginsenosides delay the progression of lung tissue injury by scavenging free radicals, mitigating oxidative damage, and simultaneously promoting the recovery of intracellular antioxidant enzyme activities such as SOD (74,75). Sugar-free hawthorn granules (SGG) effectively reverse decreased SOD activity and reduced glutathione peroxidase (GSH-Px) levels by upregulating nuclear factor E2-related factor 2 (Nrf2) protein expression, thereby mitigating oxidative stress damage in lung tissue (76). Most clinical studies on single botanical drugs such as andrographolide and Salvia miltiorrhiza extract are small-sample RCTs or observational studies conducted in single centers, lacking high-quality multi-center evidence. Key methodological flaws include non-standard randomization (e.g., only simple random allocation without concealment) and the absence of double-blind or placebo-controlled designs, leading to an increased risk of bias. Other forms of botanical drugs interventions Astragalus injection can target and activate α7-nicotinic acetylcholine receptors (α7nAChR), exerting anti-inflammatory effects by modulating macrophage polarization and inhibiting NF-κB signaling pathway activation (77). Volatile oil components in dried tangerine peel (e.g., limonene) promote airway mucus clearance and reduce the risk of atelectasis, particularly demonstrating significant improvement in sputum retention following prone position surgery, thereby supporting postoperative pulmonary care (78). Perilla, meanwhile, alleviates pulmonary inflammation and oxidative stress damage by activating the cyclic guanosine monophosphate-adenylate cyclase (cGAMP)/stimulator of interferon genes (cGAS/STING) signaling pathway and reducing ROS production (79). Botanical preparations such as Huangqi Injection, Pericarpium Citri Reticulatae volatile oil and Perilla have shown preliminary potential in the prevention and treatment of PPCs. However, the current relevant research foundation is weak and fragmented. Most studies are preclinical animal experiments or small-scale clinical pilot trials, and there are still no large-sample, well-designed RCTs to confirm their clinical efficacy and safety. Conclusions The pathogenesis of PPCs in thoracic surgery is complex, involving the interaction of multiple factors and pathological processes. Risk factors include patient variability, surgical type, and perioperative management. Pathologically, inflammatory responses, oxidative stress, alveolar injury, and airway obstruction mutually influence and exacerbate each other, and these interactions play a central role in PPCs development. This understanding provides novel targets for clinical intervention and establishes a theoretical foundation for developing new therapeutic strategies. Current research exhibits variations in mechanism focus and is constrained by the heterogeneity of PPCs definitions and surgical types across studies. Developing comprehensive and precise prevention and treatment strategies remains a key priority for future research. Botanical drugs exhibit multi-target and multi-pathway properties, and rational formulation can yield synergistic effects that allow for the concurrent modulation of interconnected pathological processes underlying PPCs—an effect that is challenging to achieve with single-target Western pharmaceutical agents. However, it should be noted that most studies on botanical drugs for the prevention and treatment of PPCs have reported significant positive therapeutic effects, such as regulating inflammatory responses, alleviating oxidative stress, and modulating immune function. Although these characteristics provide valuable supplementary strategies for the prevention and management of PPCs, the excessive presentation of positive results may suggest potential publication bias. Such publication bias may overestimate the actual efficacy of botanical drugs and undermine the reliability of cumulative evidence. Therefore, future research should emphasize the transparent reporting of both positive and negative outcomes. Meanwhile, compared with Western methodological standards, the inherent methodological limitations in current research on botanical drugs for PPCs compromise the reliability of the evidence. Some botanical drugs have not shown significant benefits in the prevention and treatment of PPCs in surgical populations, and potential safety concerns also exist. These contradictory results and safety risks are closely associated with the inherent limitations of current research. Most clinical studies are designed as single-center trials with small sample sizes, resulting in insufficient statistical power. RCTs often suffer from non-standard randomization methods, lack of blinding, and selective outcome reporting, leading to a high risk of bias. Future research should focus on conducting large-sample, multicenter RCTs in accordance with international standards, incorporating strict random sequence concealment, appropriate blinding, and comprehensive outcome reporting. At the same time, developing strategies for the combined application of botanical drugs is equally critical. In summary, future prevention and treatment of PPCs should advance synergistically through three dimensions: reducing preoperative risk factors, deepening research into pathological mechanisms, and innovating integrated Chinese-Western medicine strategies. By elucidating the synergistic mechanisms between Chinese and Western medicine, promoting standardized application, and exploring combined treatment strategies, we can improve postoperative outcomes for thoracic surgery patients. This approach will fully leverage the potential of Chinese herbal medicine in PPCs prevention and treatment, establish a more comprehensive diagnostic and therapeutic system, and deliver safer, more effective treatment options for patients. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0285/prf